Episode 6 - Antithrombotic Strategies in Comorbid Atrial Fibrillation and CHD

This activity is funded by Bayer AG and is not intended for a UK audience

Part VI of the course in pharmacotherapy in atrial fibrillation (AF) is highlighting one of the most prevalent co-morbidities to AF, namely coronary heart disease. A patient case is presented that highlights the therapeutic challenges physicians face when AF patients need a PCI, or when a NSTEMI patient suddenly develops AF. The overarching principle is to balance the ischemic risk in a given patient against the bleeding risk, an approach that deals with personalized medicine. A number of therapeutic flow-charts are provided to guide us through the recommended dual antiplatelet as well as triple antithrombotic therapy options.